Oxidative Medicine and Cellular Longevity
Volume 2016 (2016), Article ID 9324085, 14 pages
http://dx.doi.org/10.1155/2016/9324085

Review Article

Therapeutic Potential of Curcumin for the Treatment of Brain Tumors

Neil V. Klinger¹ and Sandeep Mittal1,2,3

¹Department of Neurosurgery, Wayne State University, Detroit, MI, USA
²Department of Oncology, Wayne State University, Detroit, MI, USA
³Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA

Received 23 July 2016; Accepted 7 September 2016

Academic Editor: Mohamed Essa

Copyright © 2016 Neil V. Klinger and Sandeep Mittal. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract.

Brain malignancies currently carry a poor prognosis despite the current multimodal standard of care that includes surgical resection and adjuvant chemotherapy and radiation. As new therapies are desperately needed, naturally occurring chemical compounds have been studied for their potential chemotherapeutic benefits and low toxicity profile. Curcumin, found in the rhizome of turmeric, has extensive therapeutic promise via its antioxidant, anti-inflammatory, and antiproliferative properties. Preclinical in vitro and in vivo data have shown it to be an effective treatment for brain tumors including glioblastoma multiforme. These effects are potentiated by curcumin’s ability to induce G2/M cell cycle arrest, activation of apoptotic pathways, induction of autophagy, disruption of molecular signaling, inhibition of invasion, and metastasis and by increasing the efficacy of existing chemotherapeutics. Further, clinical data suggest that it has low toxicity in humans even at large doses. Curcumin is a promising nutraceutical compound that should be evaluated in clinical trials for the treatment of human brain tumors.

1. Introduction

Primary central nervous system tumors have an incidence of 27.86 per 100,000 [1]. Glioblastoma (GBM) is the most common malignant primary CNS tumor with an annual incidence of 3.19 per 100,000. GBM accounts for 15.4% of all primary brain tumors and 45.6% of primary malignant brain tumors [1, 2]. The current standard of care for GBM consists of surgical resection followed by the Stupp regimen (adjuvant chemotherapy and radiation) and it has been used in practice for over a decade without substantial improvements. This aggressive multimodal treatment prolongs median overall survival to 15 months [3–5]. Other therapies approved for use in GBM include alternating electrical fields produced by Optune Therapy (Novocure Inc.), further prolonging median survival to 20 months [6]. With such poor prognoses, additional therapeutics are needed to improve survival and quality of life for patients with malignant gliomas. Complementary medicine and nutraceuticals are of particular interest and have been studied extensively as anticancer agents because they are usually associated with low toxicity profiles. This allows them to be safely used at high doses or added to existing chemotherapy regimens as adjuvant treatment.

Curcumin is found in rhizome of turmeric (Curcuma longa), which is a member of the ginger family (Figure 1) [7]. Its traditional uses, long known by Ayurvedic medicine from India and traditional Chinese medicine, include treating infections, liver and skin disorders, dressing wounds, burns, and decreasing inflammation [7]. In fact, powdered Curcuma longa has been used in Asian medicine, cosmetics, and fabric dying for more than 2000 years [8]. Curcumin possesses multiple beneficial chemical properties, including antioxidant, anti-inflammatory, and chemotherapeutic potential both against cultured cells and in treatment studies using animal models. Current data suggests that curcumin may be useful in a wide spectrum of human disorders including Alzheimer’s disease, Parkinson’s disease, diabetes, cardiovascular disease, arthritis, and various neoplasms including brain tumors [9, 10].

Figure 1: (a) Curcuma longa from Koehler’s Medicinal Plants, 1887. (b) From top to bottom, curcumin in its enol form, curcumin in its keto form, demethoxycurcumin, and bisdemethoxycurcumin.

2. Mechanism and Preclinical Data

Curcumin’s effects on glioma cells in vitro and in vivo have been well studied. Curcumin has many molecular targets (Figure 2) and therefore diverse and complex mechanisms of action. The antitumoral effects of curcumin are thought to act through many different signaling pathways such as cellular proliferation [11–13], apoptosis [11, 12, 14], autophagy [15–17], angiogenesis [18–20], immunomodulation [21], invasion [14, 22, 23], and metastasis [24–26]. These pathways have been reviewed comprehensively elsewhere [27–31]. In addition to its effectiveness as an antineoplastic, curcumin has been found to be protective against reactive oxygen species (ROS). A study by Rathore et al. [32] examined the effects of curcuma oil on a transient ischemia model in Sprague-Dawley rats. The middle cerebral artery was occluded using a nylon filament for two hours, followed by a 24-hour reflow period. Treatment with curcuma oil reduced the size of infarcted cerebral tissue, improved neurologic function, and reduced oxidative stress caused during the reperfusion period. The authors reported that these protective effects were obtained by inhibition of ROS, reducing peroxynitrite levels and caspase-3 activity and preventing destabilization of the mitochondrial membrane potential [32]. In an in vitro model of ischemia-reperfusion using rat cortical neurons, curcumin was found to protect neurons from death caused by oxygen and glucose deprivation. The authors of this study suggested that curcumin activates an antioxidant protein, thioredoxin, in the Nrf2 pathway [33]. In addition, curcumin may inhibit cellular glyoxalases leading to decreased ATP and glutathione, which can impact cellular metabolism and may account for some of its anti-inflammatory and antitumor effects [34].

Figure 2: Cancer pathway targets affected by curcumin. When the listed targets have multiple contributions to tumorigenesis (e.g., NF-κB), they are only placed under one category. Figure modified from Davis et al. 2003 [44]. As permitted by Creative Commons Attribution-NonCommercial-Share Alike 3.0 license and BJC OPEN initiative. ABCG2: ATP-binding cassette subfamily G member 2; AKT: protein kinase B; AP-1: activator protein 1; BAK: Bcl-2 homologous antagonist/killer; BAX: Bcl-2-like protein 4; Bcl-2: B-cell lymphoma 2; Bcl-xL: B-cell lymphoma-extra large; caspase: cysteine-aspartic protease; CD105: endoglin; CD31: platelet endothelial cell adhesion molecule (PECAM-1); CDC: cell division cycle; CDK: cyclin-dependent kinase; CDKI: cyclin-dependent kinase inhibitor; CHK1: checkpoint kinase 1; c-Myc: v-Myc avian myelocytomatosis viral oncogene homolog; COX-2: prostaglandin-endoperoxide synthase 2; CXCR-4: C-X-C chemokine receptor type 4; EGFR: epidermal growth factor receptor; EGR-1: early growth response protein 1; ERCC-1: excision repair cross-complementation group 1; ERK: extracellular signal-regulated kinases; FGF: fibroblast growth factor; GLI1: GLI family zinc finger 1; HDAC: histone deacetylases; HIF1A: hypoxia inducible factor 1, alpha subunit; hTERT: telomerase reverse transcriptase; ICAM-1: intercellular adhesion molecule 1; IL: interleukin; JAK: Janus kinase; JNK: c-Jun N-terminal kinase; MAPK: mitogen-activated protein kinases; MMP: matrix metalloproteinases; MRP: multidrug resistance protein; mTOR: mechanistic target of rapamycin; NF-κB: nuclear factor kappa-light-chain-enhancer of activated B cells; Nrf2: nuclear factor (erythroid-derived 2) like 2; PI3K: phosphatidylinositol-4,5-bisphosphate 3-kinase; PTCH1: patched 1; SAC: spindle assembly checkpoint; SHH: sonic hedgehog; Snail: zinc finger protein SNAI1; STAT-3: signal transducer and activator of transcription 3; TIMP: tissue inhibitors of metalloproteinases; TNF: tumor necrosis factor; uPA: urokinase; VEGF: vascular endothelial growth factor.

2.1. Curcumin Induces G2/M Cell Cycle Arrest

There is a bevy of data to suggest that curcumin is able to induce G2/M cell cycle arrest and apoptosis. More recent work has tried to explain how this cell cycle arrest can occur. Wu et al. published a study in 2013 [35] that suggests that this might be due to increased DAPK1 expression. The authors treated the U251 GBM cell line with curcumin and found a dose-dependent increase in DAPK1 mRNA by real-time RT-PCR and verified a corresponding increase in protein expression by western blot analysis. Further, they used siRNA (si-DAPK1-1 and si-DAPK1-2) transfection to suppress DAPK1 and found that curcumin had an attenuated ability to suppress STAT3 and NF-κB phosphorylation. They also showed that their knockdown of DAPK1 inhibited curcumin-mediated caspase-3 activation and led to decreased apoptosis (33.0% apoptotic cells versus 58.3% in their control) [35]. These findings suggest that DAPK1 plays an important role in curcumin-mediated cell death. Other studies in U251 GBM cells show that p53 expression is upregulated by curcumin treatment, as were CDKi (p21) and ING4—a tumor suppressor gene that has been found to be suppressed in gliomas [36, 37]. Curcumin owes part of its antiproliferative effects to suppression of cyclin D1 and to induction of p21. In a study that treated U87 GBM cells with curcumin, transcription factor Egr-1 was found to activate transcription of p21 independent of p53 activation. Egr-1 expression was reportedly induced by curcumin via ERK and JNK [13]. An in vitro study using U87 human glioma cell line showed that 5–10 μM curcumin could inhibit proliferation and that treated cells were arrested in G2/M stage by increased expression of DUSP-2 and inhibition of ERK and JNK phosphorylation. Interestingly, trapping cells in the G2/M phase appears to enhance their sensitivity to radiation [38, 39]. Curcumin’s radiosensitizing effects have also been examined in neuroblastoma (SK-N-MC) cells. Pretreating cells with 100 nM curcumin suppressed radiation induced NF-κB, enhanced radiation induced caspase activation, and inhibited antiapoptotic molecules [40].

2.2. Curcumin Activates Apoptotic Pathways

An in vitro study using human GBM (A172, KNS60, U251MG(KO)) and medulloblastoma (ONS76) cell lines showed that while curcumin was able to inhibit growth of these cell lines, only KNS60 and ONS76 were arrested at G2/M. These findings suggest that the mechanism for growth inhibition is not exclusively due to cell cycle arrest. They also found a significant increase in caspase 3/7 activity, curcumin induced DNA damage, and apoptosis triggered by overexpression of BAX and downregulating Bcl2 and survivin, as well as inhibition of telomerase and downregulation of hTERT [41]. An in vitro study using 8401 GBM cell line found that curcumin decreased cell proliferation, reduced mitochondrial membrane potential, induced DNA fragmentation, induced apoptosis via a caspase-dependent pathway (caspase-3, caspase-8, and caspase-9), and inhibited NF-κB transcription factor activity [42]. In U87MG GBM cell line, curcumin can induce apoptosis by suppressing antiapoptotic signals, by promoting activation of caspase-8, and through an increased BAX/Bcl-2 ratio [43]. Solubilized curcumin (667 μM in PBS, 3% DMSO) can increase caspase 3/7 activity in both mouse (B16F10 melanoma, GL261 glioma, and N18 neuroblastoma) and human (HOG oligodendroglioma and A549 lung cancer) cell lines and it decreased tumor cell viability as measured by MTT assay. Further, LDH release in these experiments was not increased, suggesting apoptotic cell death [19]. The authors of this study also report that cyclin D1, NF-κB, AKT, ERK, and Bcl-xL were suppressed when B16F10 cells were treated with curcumin [19]. In an in vivo arm of this experiment, the authors injected 10,000 B16F10 mouse melanoma cells in the brain of C57BL/6 mice. They then received either daily tail vein injections of 200 μL of their solubilized curcumin (estimated final plasma concentration of 35 μM in PBS, 0.15% DMSO) or a control injection (PBS, 0.15% DMSO) for 18 days. Additionally, this experiment was repeated with intracerebral delivery of the curcumin solution via a stainless steel cannula. While all of the control animals developed intracranial tumors, only one of the 5 treated mice developed detectable tumor [19].

2.3. Curcumin Induces Autophagy

Autophagy is a cellular process for disassembling unnecessary or dysfunctional cellular components and is essential for maintaining energy during states of nutritional stress and during programmed cell death. It also appears to have an important role in regulation of glioma-initiating cells, which are poorly differentiated and share features of neural stem cells. An in vitro study published in 2012 showed that curcumin can induce differentiation and halt growth of glioma-initiating cells (SU-2 and SU-3) from surgically resected human GBM by activating autophagy. In the same study, glioma-initiating cells were implanted intracranially in athymic nude mice and randomized to a treatment group consisting of intraperitoneal (IP) injection of curcumin (300 mg/kg) every 3 days or control group ( each). Those mice who received treatment had increased survival (study halted after 120 days) versus nontreated animals [16]. In a separate study, curcumin activated the ERK1/2 pathway and inhibited the AKT/mTOR/p70S6K pathway, resulting in autophagy both in vitro and in vivo using a subcutaneous xenograft model in nude mice with U87 cells. The authors report that curcumin induced G2/M cell cycle arrest in addition to autophagy in U87 and U373 GBM cells [17].

2.4. Curcumin Disrupts Molecular Signaling

The NF-κB pathway is upregulated in GBM, and inhibitors of NF-κB exhibit relatively low toxicity to normal tissues. A preclinical study of NF-κB inhibitors found that NF-κB activity correlated with percentage cell viability in C6 and U138 GBM lines [45]. The authors report that inhibition of NF-κB leads to mitochondrial dysfunction with arrest in the G2/M phase of the cell cycle. Interestingly, NF-κB is found to be overstimulated in cisplatin-resistant C6 cells and NF-κB inhibitors were able to overcome cisplatin resistance [45]. Similarly, progranulin has been found to be overexpressed in many GBM cell lines (U87, GBM8904, and S1R1) and tumor samples [46]. Progranulin overexpression contributes to tumorigenesis and treatment resistance by upregulating DNA repair and stemness genes using the transcription factor AP-1. Curcumin is an AP-1 inhibitor, and it was found to downregulate progranulin promoter activity and expression [46]. Other studies have shown that curcumin can reduce GBM cell survival through inhibition of AP-1 and NF-κB by preventing constitutive activation of JNK and AKT [47]. An in vitro study examined the role of glucose-6-phosphate translocase (G6PT) in U87 GBM cell signal transduction. In this experiment, suppression of gene expression was accomplished using siRNAs and led to apoptosis and necrosis. Curcumin (35 μM) also inhibited G6PT gene expression >90%. However, the authors also report transfection with an expression vector for G6PT rescued cells from curcumin-mediated cell death. This suggests that G6PT may be a novel chemotherapeutic target and that G6PT overexpression may lead to treatment resistance [48]. In a separate set of experiments, murine glioma cell lines (Tu-2449, Tu-9648, and Tu-251) with constitutively expressed STAT3 treated with curcumin showed a dose-dependent decrease in the activity of phosphorylated JAK1 and JAK2 and led to downstream inactivation of STAT3. In an in vivo arm of this study, C6B3F1 mice were fed a diet rich in fat and cholesterol with or without fortification with curcumin for 7 days. Subsequently, they received intracranial implantation of either Tu-2449 or Tu-9648 glioma cells and maintained their diet. Fifteen percent of Tu-2449 implanted mice who received curcumin-enriched diets had tumor-free long-term survival versus 0% of the control dieted animals. Curcumin fed Tu-9648 implanted mice experienced a 38% increase in tumor-free long-term survival [49].

The sonic hedgehog (SHH) signaling pathways are important in the carcinogenesis of medulloblastoma. It is a major regulator of cell proliferation and death. Curcumin has been shown to downregulate SHH, leading to decreased downstream targets GLI1 and PTCH1 and cytotoxicity in cell lines MED-4, MED-5, and DAOY [50]. Targeting SHH and GLI1 with curcumin treatment has also been done in glioma cells (U87 and T98G). Similar to medulloblastoma, mRNA and protein levels of SHH and GLI1 were downregulated with curcumin treatment. IP injection of curcumin in U87-implanted nude mice also reduced tumor volume, prolonged survival, and decreased GLI1 expression [51]. In the medulloblastoma cell line DAOY, curcumin has been shown to inhibit Wnt/β-catenin signaling and suppress proliferation with IC₅₀ of 35 μM after 48 hours [52]. Mechanistically, curcumin may decrease histone deacetylase 4 expression leading to increased tubulin acetylation and mitotic catastrophe in addition to its effects on G2/M cell cycle arrest in DAOY medulloblastoma cells [53].

2.5. Curcumin Decreases Invasion and Metastasis

Abnormal expression of matrix metalloproteinases (MMPs), membrane-associated or secreted enzymes used to digest extracellular matrix proteins, is one method by which glioma cells are able to invade normal brain tissue. Data has shown that curcumin is able to suppress expression of MMP-1, MMP-3, MMP-9, and MMP-14 in GBM cell lines U87MG and U373MG via the common upstream AP-1 and MAP kinases [22, 23, 54]. Urokinase-type plasminogen activator (uPA) is a serine protease that starts a degradative cascade by converting extracellular plasminogen to plasmin and eventually degrades extracellular matrix collagen and activates other MMPs to aid in invasion [55]. Curcumin can prevent nuclear translocation of RelA/NF-κB, which prevents upregulation of uPA [55]. Curcumin has also been found to dramatically reduce MMP-9 in murine glioma cell lines Tu-2449, Tu-9648, and Tu-251 [49]. An important contributor to tumors propensity to invade and metastasize is angiogenesis. Cell lines derived from surgically resected pituitary adenomas treated with curcumin have decreased HIF1A and VEGFA, both of which are involved in tumoral angiogenesis [56].

2.6. Curcumin Increases the Efficacy of Existing Chemotherapeutics

Data also exists to suggest that curcumin acts synergistically with chemotherapeutics already approved for the treatment of brain tumors. A preclinical study examined the efficacy of curcumin for the treatment of GBM in vitro and in vivo [57]. Cell lines U138MG, U87, U373, and C6 were treated with curcumin and found to have IC₅₀ values of 29, 19, 21, and 25 μM, respectively, whereas IC₅₀ for astrocytes was 135 μM. Chemotherapy synergism was subsequently tested using U138 and C6 cell lines. Curcumin alone resulted in 55% and 75% viability, respectively. When cisplatin was added in combination with 25 μM curcumin, the viability dropped to 30% and 10% for U138 and C6 cell lines, respectively. When doxorubicin was added in combination with 25 μM curcumin, viability was reported to be 36% and 46%. Mechanistically, the authors reported that curcumin decreased activation of PI3K/AKT and NF-κB pathways, decreased expression of Bcl-xL, and caused mitochondrial dysfunction and apoptosis. The authors also implanted Wistar rats with C6 GBM cells intracranially and treated them with 50 mg/kg/day curcumin via IP injection within days 10–20 after implantation. Sixty-four percent of curcumin treated animals developed tumors as compared to 100% of the DMSO treated controls. Of the treated animals who developed tumors, average tumor volume was 73% less than that of the controls [57]. Curcumin in combination with temozolomide (TMZ) appears to have additive cytotoxic benefit in GBM cells [15]. Further, both drugs appear to cause G2/M arrest by activating proteins such as Wee, Cdc2, CHK1, and Cdc25c. Decreased phosphorylation of cyclin B1 and cyclin D1 was also observed [15]. The authors found that treatment with either TMZ or curcumin appears to induce autophagy that was dependent on ERK1/2 prior to apoptosis. Curcumin was also found to inhibit STAT3, NF-κB, and PI3K/AKT [15]. A study by Ramachandran et al. [58] investigated potentiation of etoposide (ETP) and TMZ by curcumin and a trade preparation of turmeric called Tumeric Force™ (TF) in human U87 GBM and D283 medulloblastoma cell lines. U87 IC₅₀ values for ETP, TMZ, curcumin, and TF were 6.5, >2000, 37.3, and 30.8 μg/mL, respectively. For D283 cells, those IC₅₀ values were 0.19, 147, 28.7, and 1.6 μg/mL. Combination index values in U87 glioma cells for ETP + curcumin, TMZ + curcumin, and ETP + TMZ + curcumin were 0.55, 2.07, and 0.39 μg/mL, respectively. The combination index values with TF instead of curcumin were 0.38, 0.57, and 0.05 μg/mL [58]. Curcumin has also been studied for efficacy in combination with paclitaxel (PTX) for the treatment of GBM. LN18 and U138MG cell lines treated with 20 μM curcumin and 10 nM PTX were found to have a combination index of 0.1 and 0.09, respectively, indicating a synergistic effect. This combination activated caspase-3, caspase-8, and calpain, increased BAX, and reduced Bcl-2 initiating apoptosis. Combination therapy also decreased the ability of LN18 and U138MG cells to invade matrigel [59]. In addition to acting synergistically, curcumin may prevent chemotherapy resistance. A study reported in 2008 on Sprague-Dawley rats showed curcumin can inhibit a protein linked with multidrug resistance in the luminal membrane of capillaries at the blood-brain barrier- (BBB-) ATP-binding cassette transporter ABCG2 [60]. A separate, intriguing method by which GBM may resist hydrophobic therapeutic agents is by accumulating lipid droplets that sequester these drugs. Curcumin is hydrophobic and has been shown to concentrate near the cell membrane and in cytoplasmic droplets of U251N human GBM cells [61]. Zhang et al. sought to overcome this mechanism of resistance in vitro using pyrrolidine-2, a cytoplasmic phospholipase A2α inhibitor, in combination with curcumin. When the cells were pretreated with pyrrolidine-2 24 hours before curcumin administration, cell viability was found to approach 0% [61].

2.7. Curcuminoids and Curcumin Derivatives

Demethoxycurcumin (C2) and bisdemethoxycurcumin (C3) (Figure 1) are two curcuminoids often found in small percentages of curcumin extractions. An in silico study published in 2009 [62] examined the docking of curcuminoids with the Bcl-2 apoptotic proteins (Protein Data Bank accession numbers 1G5M and 1GJH). The authors calculated free energies and inhibition constants for these molecules and found that C2 binds more favorably than curcumin (  −6.97 versus −4.53 kcal/mol; 0.56 versus 2.21 nm). In vitro treatment of U87 GBM cells showed marked decrease in Bcl-2 expression with all three compounds after 48 hours and that C2 showed significant progression of percent apoptosis compared to curcumin or C3. An in vitro binding assay utilizing circular dichroism spectroscopy showed that C2, like the natural Bcl-2 inhibitor Bak, caused a conformational change different from curcumin or C3 [62]. These findings suggest that C2 induces Bcl-2 mediated apoptosis more effectively than curcumin or C3. A study published by Huang et al. [63] also examined the effects of C2. They showed that C2 had IC₅₀ of 22.7 μM in GBM 8401 cells and that apoptosis was induced by decreasing the mitochondrial membrane potential and caspase-dependent pathways similar to other studies of curcumin [63]. Other curcumin analogs have been developed in an attempt to improve upon the compound’s therapeutic promise. For example, lead compounds identified by Campos et al. show comparable IC₅₀ values against GBM (U87MG) and neuroblastoma (SK-N-SH and SK-N-FI) cell lines [64].

3. Delivery Mechanisms

The therapeutic benefits of curcumin are limited by its poor absorption, rapid metabolism, and poor water solubility [65]. Curcumin is broken down by multiple enzymatic pathways, including glucuronidation, sulfation, alcohol dehydrogenase, and p450 system leading to rapid metabolism and excretion [66]. However, its lack of toxicity allows for administration of large doses. Twenty-four subjects with mean age of 34 were provided capsules with 0.5–12 g of curcumin and serum analysis was conducted prior to testing at 1, 2, and 4 hours after dosing. Peak serum concentration was <2 μM even at 10- and 12-gram doses [67, 68]. These clinical data also show that doses up to 12 grams per day do not provoke serious side effects, though trouble with tablet bulk, diarrhea, and yellow stool were noted [67, 68]. Piperine, an inhibitor of hepatic and intestinal glucuronidation, has long been suggested to be administered as an adjuvant to prevent the degradation of medications including curcumin [69–71]. Ten subjects with mean age of 60 years participated in a randomized crossover trial to compare the effects of oral curcumin (2 g) alone or with the addition of piperine (20 mg). A two-week washout period was used before the crossover. They found that, when administered with piperine, peak serum concentrations of curcumin increased 30-fold and the relative bioavailability was 2000%. The for curcumin administered with piperine was 203 L/kg. No adverse events were reported in this study [69].

Though current literature contains mixed data, curcumin distribution to the brain might be hindered by limited BBB permeability [65, 72]. Certain nanoparticle formulations, such as poly(lactic-co-glycolic acid), have been shown to increase distribution to brain tissue [65]. The half-life of curcumin-loaded poly(lactic-co-glycolic acid) in brain tissues from Sprague-Dawley rats for this study was reported to increase from 9 minutes to 15 minutes. When brain regions were examined separately, the compound’s half-life was found to be significantly extended in the cerebral cortex (20 versus 2 minutes) and hippocampus (17 versus 8 minutes) but not in the cerebellum, brainstem, striatum, or other brain regions [65]. Curcumin has also been loaded into poly(butyl)cyanoacrylate (PBCA) nanoparticles using apolipoprotein E3 to increase transport across the BBB [73]. This delivery system was found to induce apoptosis in SH-SY5Y neuroblastoma cells more efficaciously than curcumin solution or curcumin loaded in the PBCA carrier without ApoE3 [73]. Nanostructured lipid carriers (tripalmitin-oleic acid) loaded with curcumin had IC₅₀ of approximately 20 μg/mL against A172 GBM cells compared to IC₅₀ of 80 μg/mL with curcumin alone. Further, the authors showed that curcumin delivered with the lipid carriers to subcutaneous flank tumor bearing nude mice decreased tumor volume by 82% [74]. Polymeric micelles have also been studied for curcumin delivery. Amphiphilic block copolymers form micelles when placed in aqueous solutions. These vesicles, or polymersomes, can be made of one or more different high-molecular weight amphiphilic block copolymers such as oleic acid and PEG 400 as a diblock nanostructure. This combination has been shown effective in delivering curcumin and reducing tumor burden in mouse models [75, 76]. Monomethoxy PEG has a higher molecular weight of 2 kDa versus 400 Da and has also been tested in attempt to obtain a better thermodynamic profile [77]. When tested in vitro with the U87 human glioblastoma cell line, monomethoxy PEG-oleate conjugation product showed IC₅₀ values of 24 μM versus IC₅₀ of 48 μM for free curcumin [77]. Intranasal delivery of therapeutics to the brain represents a noninvasive way to bypass the BBB. Exosome encapsulated curcumin has been administered intranasally to C57BL/6j mice in an attempt to treat inflammation induced by administration of lipopolysaccharide (LPS) [78]. It was found that these exosomes were taken up by brain microglia within 15 minutes and inhibited LPS-induced inflammation [78]. Other lipid carriers have also been designed for intranasal curcumin delivery to the central nervous system. Testing in Wistar rats showed that maximum concentration was reached after approximately 3 hours, and delivery to brain tissues was greater with the lipid carrier than the plain drug suspension (86 and 54 ng/g, resp.) [79].

Dendrosome carriers, comprised of esterified oleoyl chloride and polyethylene glycol 400, have recently been published as effective means of delivery curcumin [75, 76]. In vitro data treating U87MG GBM cells with curcumin, dendrosomal curcumin, and empty dendrosome found that dendrosomal curcumin had superior efficacy at 24, 48, and 72 hours. As with many other studies, the authors found increased caspase activity when these cells were treated with curcumin. Interestingly, they also examined pluripotency transcription factors (OCT4A, OCT4BI, SOX-2, and Nanog) and found that treating U87 cells with dendrosomal curcumin led to significant decreases in these factors. During cellular differentiation, miR-145 expression suppresses these pluripotent genes. The authors reported that dendrosomal curcumin was able to exert its effects by inciting an approximately 35-fold elevation of miR-145 [75]. Treatment of A431 (epidermoid carcinoma) and WEHI-164 (mouse fibrosarcoma) cell lines with dendrosomal curcumin resulted in IC₅₀ values of 14.3 and 7.5 μM at 48 hours, respectively, compared to 37 μM for curcumin alone against WEKI-164 cells [76]. WEHI-164 cells were injected subcutaneously in the flank in an in vivo experiment using BALB/c mice, and the results showed that treatment with dendrosomal curcumin led to significant reductions in tumor burden compared to curcumin treated animals or control [76]. Dendrosomal curcumin has also shown efficacy in the treatment of metastatic breast cancer cells (4T1) in vitro and in vivo with 11% of animals having metastases at necropsy compared to 89% of control. The authors also reported that treatment with dendrosomal curcumin led to downregulation of VEGF, COX-2, and MMP expression [80].

Curcumin has also been conjugated as a poly(glycerol-sebacate-curcumin) polymer similar to carmustine polymers used for local treatment with gliomas [81]. In vitro studies show IC₅₀ values in response to this polymer of 23.2 μg/mL with U87 cells and 20.2 μg/mL with T98 cells [81]. Polycaprolactone implants have been studied as another delivery method for test agents with poor bioavailability. An in vitro assay with 9 L rat glioma cells reported that curcumin-loaded poly(ɛ-caprolactone)-poly(ethylene glycol)-poly(ɛ-caprolactone) nanofibers caused dose-dependent growth inhibition [82]. Gupta et al. reported a preclinical study [83] in August-Copenhagen Irish rats who received four polycaprolactone implants that were loaded with 40 mg of curcumin. Analysis of liver, brain, and plasma by high-performance liquid chromatography (HPLC) with fluorescence spectroscopy showed an increase in curcumin levels versus animals receiving sham implant and a diet supplemented with 1000 ppm curcumin [83]. They also demonstrated that these implants can reduce benzo[a]pyrene induced lung DNA adducts by 62% in Sprague-Dawley rats [83].

Curcumin microparticles in a poly(D,L-lactide-co-glycolide) polymer has been formulated in an attempt to improve delivery of the drug and sustain its release. The investigators reported that a single subcutaneous injection was able to sustain release in the blood and body tissues of BALB/c mice for 4 weeks. Levels of curcumin in the lungs and brain show 10–30-fold greater distribution than the blood. Further, animals implanted with MDA-MB-231 human breast adenocarcinoma cells were effectively treated with these microparticles (49% decreased tumor volume versus empty microparticle), whereas repeated systemic injections of curcumin alone were no different than the vehicle treatment [84]. Curcumin nanoparticles (NanoCurc™) [21, 85] have also been used as a method to overcome the delivery and bioavailability barriers of curcumin. These particles, unlike free curcumin, are able to disperse in an aqueous environment [21]. Studies using xenograft models of human pancreatic cancer in athymic mice show that NanoCurc™ can lead to approximately 50% reduction in tumor volume. This inhibition was enhanced with the addition of gemcitabine. The authors reported that these effects were observed through decreased NF-κB activation, MMP-9, and cyclin D1 [85]. These nanoparticles have also been shown to suppress in vitro growth by MTS cell proliferation assay of embryonal tumor lines (DAOY and D283Med), U87 GBM cells, and glioblastoma neurosphere lines (JHH-GBM14 and HSR-GBM1) in a dose-dependent manner [86]. The authors suggested that, in this experiment, the effects could be due to a combination of G2/M arrest and apoptotic induction [86].

Additional benefits of using delivery systems include the ability to deliver multiple compounds simultaneously. For example, Dilnawaz and Sahoo used magnetic nanoparticles (MNP) to deliver both curcumin and TMZ to monolayer and spheroid T-98G GBM cultures. In monolayer cultures, IC₅₀ values (μg/mL) for TMZ, curcumin, TMZ and curcumin were 1.1, 6.6, and 0.8 without MNP delivery and 0.2, 0.6, and 0.1 with MNP delivery. These same values in spheroid cultures were 23, 28, and 10 without MNP and 10, 11, and 5.2 with MNP delivery. Combination index analysis showed that the drug combination functioned synergistically in both cultures [87]. Another study using magnetic core nanocapsules reported the ability to deliver drugs with differing hydrophobicity [88]. They were able to accommodate doxorubicin (hydrophilic) and curcumin (hydrophobic) in the same particles for delivery to RG2 rat glioma cells [88].

Curcumin has also been coupled to an antibody as a delivery vehicle. Langone et al. [89] demonstrated that curcumin coupled to Muc18, a melanoma specific antibody, increased its efficacy against B16F10 melanoma. The in vitro IC₅₀ value was reduced from 22 μM to 0.09 μM in cells treated with the curcumin-antibody adduct versus curcumin alone. In addition, C57BL/6 mice implanted with 1,000 B16F10 cells in their right forebrain showed a 10-fold decrease in tumor burden when treated with and curcumin-antibody adduct [89]. The authors reported that this effect was achieved by suppressing NF-κB [89]. In 2014, Langone et al. published another study that used an antibody delivery system for curcumin. In this experiment, a GBM-specific CD68 antibody was used to target GL261 (mouse), T98G (human), and U87MG (human) GBM cells [18]. GL261 cells were treated in vitro with 50 μM of curcumin for 24 hours, and western blot analysis showed suppression of NF-κB. In addition, curcumin was found to inhibit AKT-1 (neural survival and antiapoptotic), Bcl-xL (antiapoptotic), cyclin D1 (cell cycle promoter), and VEGF (promoting angiogenesis) [18]. Curcumin alone yielded IC₅₀ 15 μM, whereas treatment with the curcumin-antibody adduct had IC₅₀ of 0.125 μM. IC₅₀ values for U87MG and T98G cells were 25 and 8 μM for curcumin alone and 0.400 and 0.225 μM, respectively, for treatment with the CD68 antibody-linked curcumin. GL261 cells were also implanted in the right forebrain of C57BL6 mice. These mice were treated with intracranial infusions of 16 pmol CD68 antibody-linked curcumin followed by tail vein infusion of curcumin and resulted in a reduction of intracranial tumor burden [18].

4. Toxicity/Safety

Natural products are of interest as anticancer agents because they have been associated with low toxicity profiles. This allows them to be safely used at high doses or added to existing regimens. Indeed, curcumin has been administered to human subjects at large doses without major side effects [67–69]. However, some data exists that serves to caution against its use. Despite being an antioxidant, curcumin may lead to a temporary increase in ROS and a decrease in cell viability by depletion of glutathione [90]. Curcumin might cause DNA base damage and fragmentation through cytochrome p450 enzyme generation of a curcumin radical and lead to apoptotic cell death in healthy as well as tumoral tissues [91]. Interestingly, this damage was attenuated when curcumin was present at larger concentrations [92]. Similar DNA damage findings have been noted during in vivo studies [93, 94]. Curcumin may inhibit the tumor suppressor p53 function in colon cancer cells and contribute to tumorigenesis [95]. Administration of curcumin with camptothecin or cyclophosphamide may inhibit their effectiveness; thus careful study of curcumin is warranted prior to its addition to an existing chemotherapy [96].

5. Clinical Data

There are over one hundred clinical trials examining the potential therapeutic effects of curcumin (Table 1, https://clinicaltrials.gov/). Many of these trials examine the efficacy of curcumin for the treatment of gastrointestinal diseases (e.g., Cohn’s disease, ulcerative colitis, and inflammatory bowel disease), endocrine disorders (e.g., diabetes mellitus), neoplasms (breast, gastrointestinal, cervical, lymphoma, and pancreatic), immune system diseases (e.g., atopy, multiple sclerosis, and rheumatoid arthritis), and psychiatric disorders (e.g., Alzheimer’s disease, schizophrenia, cognitive impairment, and depression). To date, no clinical data exist on treatment of brain tumors with curcumin despite the vast amount of promising preclinical data. A study completed in May 2013 (NCT01712542) examined the bioavailability of curcumin in patients with GBM, but results from this study have not yet been made available. Other human bioavailability data are discussed in “Delivery Mechanisms.”

Table 1: Active clinical trials assessing therapeutic benefit of curcumin.

Trial
Status
Site
Disease
Measure
Trial ID

Vascular

Curcumin or placebo
Ongoing
Lawson Health Research Institute, CA
AAA
Serum creatinine
 NCT01225094

Curcumin or placebo
Ongoing
University of Colorado Boulder, USA
Vascular aging
Arterial stiffness, arterial pulse-wave velocity, NO dilation
 NCT01968564

Curcumin or placebo
Ongoing
UPEI, CA
Vascular stiffness
Arterial stiffness by tonometry, IL-6, CRP, CK
 NCT02281981

Neurologic/psychiatric

Curcumin with or without yoga
Recruiting
VA Los Angeles, USA
AD
Biomarkers for MCI
 NCT01811381

Curcumin
Recruiting
SHSC, CA
Adolescent bipolar disorder
Mood by CDRS-R, biomarkers
 NCT01928043

Curcumin with other supplements or placebo
Ongoing
HCL, France
Fibromyalgia
QOL by GIQLI
 NCT01469936

Curcumin or placebo
Ongoing
UCLA, USA
MCI, normal aging
Cognitive changes by neuropsych assessment
 NCT01383161

Curcumin or placebo with omega-3 fatty acid
Invitation only
TUMS, Iran
Migraine
HA, endothelial factors, inflammation
 NCT02532023

Curcumin or placebo with IFN-β1A
Ongoing
Merck Serono, Italy
Multiple sclerosis
Proportion of subjects with active T2 lesions
 NCT01514370

Curcumin or placebo
Recruiting
Beersheva Mental Health Center, Israel
Schizophrenia
Psychotic symptoms (PANSS)
 NCT02298985

Curcumin
Recruiting
VA Los Angeles, USA
Schizophrenia
MCCB
 NCT02104752

Curcumin or placebo
Not yet recruiting
Yale, USA
Schizophrenia, schizoaffective
MCCB
 NCT02476708

Gastrointestinal

Curcumin or placebo with thiopurines
Recruiting
CHU, France
Crohn’s disease
Rutgeerts endoscopic score
 NCT02255370

Curcumin with triple therapy or triple therapy alone
Not yet recruiting
Rabin Medical Center, Israel
Helicobacter pylori infection
Eradication by urea breath test
 NCT02018328

Curcumin with selenium and green tea or placebo
Recruiting
Meir Medical Center, Israel
Irritable bowel syndrome
QOL by questionnaires
 NCT01167673

Curcumin or placebo
Not yet recruiting
NCI, USA
MAG and/or GIM
Changes in IL-1β, safety, tolerability, histologic grade
 NCT02782949

Curcumin or placebo
Not yet recruiting
Schneider Children’s Medical Center, Israel
Pediatric ulcerative colitis
Disease activity by PUCAI
 NCT02277223

Curcumin or placebo with 5-ASA
Recruiting
Asian Institute of Gastroenterology, India
Ulcerative colitis
Time to clinical and endoscopic remission
 NCT02683733

Curcumin or placebo with 5-ASA
Recruiting
Asian Institute of Gastroenterology, India
Ulcerative colitis in remission
Percentage of patients in remission
 NCT02683759

Oncologic

Curcumin or placebo
Recruiting
Emory University, USA
Breast cancer
NF-κB by ELISA
 NCT01740323

Curcumin at two different doses
Recruiting
OSU, USA
Breast cancer, obesity
Adherence, tolerability, safety
 NCT01975363

Curcumin or HPR Plus or placebo
Recruiting
University of Rochester, USA
Noninflammatory breast cancer
Mean radiation dermatitis severity
 NCT02556632

Curcumin with standard treatment
Recruiting
UZ Leuven, Belgium
Endometrial carcinoma
Peripheral blood inflammatory markers
 NCT02017353

Curcumin
Recruiting
Baylor Research Institute, USA
Squamous CIN3
Safety, feasibility, overall and pathologic response
NCT02554344

Curcumin and piperine
Recruiting
Mayo, USA
Cancer with inflamed ureteral stent
AE, max tolerable dose, optimal dose
 NCT02598726

Curcumin with cholecalciferol
Recruiting
Case CCC, USA
CLL or SLL, stages 0-II
Overall response rate by NCI-WG (CLL) or Cheson (SLL)
 NCT02100423

Curcumin
Recruiting
University Hospital Salzburg, Austria
Locally advanced or metastatic cancer
Safety, max tolerable dose, tumor response
 NCT02138955

Curcumin or placebo
Recruiting
UPR, Puerto Rico
FAP
Tolerability and efficacy by polyp number and size
 NCT00927485

Curcumin or placebo
Ongoing
NCI, USA
FAP
Laboratory biomarker analysis
 NCT00641147

Curcumin with anthocyanin extract
Recruiting
The Hospital Galliera, Italy
Colorectal adenoma
β-Catenin, NFkβ, Ki-67, p53 by IHC
 NCT01948661

Curcumin with 5-FU
Recruiting
Baylor Research Institute, USA
Metastatic colon cancer resistant to 5-FU
Safety, toxicity, response, biomarkers
 NCT02724202

Curcumin with FOLFOX or FOLFOX alone
Ongoing
University of Leicester, UK
Metastatic colorectal cancer
Tolerable long-term dose, safety
 NCT01490996

Curcumin with Avastin/FOLFIRI
Not yet recruiting
Gachon University Gil Medical Center, Korea
Metastatic colorectal cancer
PFS
 NCT02439385

Curcumin with irinotecan
Recruiting
UNC Lineberger, USA
Metastatic colorectal cancer
Max tolerated dose, pharmacokinetics
 NCT01859858

Curcumin or placebo with capecitabine and radiation
Ongoing
MD Anderson, USA
Rectal cancer
Pathologic complete response rate
 NCT00745134

Curcumin or placebo with docetaxel
Recruiting
Centre Jean Perrin, France
Metastatic prostate cancer
Time to progression, PSA response
 NCT02095717

Curcumin or placebo
Recruiting
UT Southwestern, USA
Prostate cancer
PSA, recurrence free survival
 NCT02064673

Curcumin or placebo with RT
Recruiting
SBUMS, Iran
Prostate cancer
Proctitis and cystitis by CTCAE, PSA
 NCT02724618

Curcumin with gemcitabine, metformin, and paclitaxel
Recruiting
City of Hope Medical Center, USA
Metastatic pancreatic cancer
Feasibility, compliance, toxicity, survival
 NCT02336087

Curcumin with EGFR-TKI
Recruiting
Lady Davis Institute, CA
Nonresectable mutant EGFR NSCLC
Feasibility, adherence, AE, QOL (FACT-L), CRP
 NCT02321293

Other

Curcumin or placebo
Recruiting
University of Colorado Denver, USA
ADPKD
Changes in FMD-BA and aortic pulse-wave velocity
 NCT02494141

Curcumin mouthwash
Recruiting
Aurora BayCare Medical Center, USA
Chemotherapy induced mucositis
AE, toxicity, pain, healing time
 NCT02300727

Curcumin or placebo
Recruiting
Lawson Health Research Institute, CA
CKD
Albuminuria, eGFR, IL-18
 NCT02369549

Curcumin or placebo
Recruiting
NNFTI, Iran
DMII
Triglyceride and CRP levels
 NCT02529969

Curcumin or placebo
Recruiting
NNFTI, Iran
DMII
Fasting blood sugar, antioxidant capacity
 NCT02529982

Curcumin with other nutraceuticals or placebo
Not yet recruiting
IRCCS Neuromed, Italy
NAFLD
ALT, AST, GGT
NCT02369536

Curcumin in Orabase
Ongoing
SVSIDS, India
Oral submucous fibrosis
Reduction of lesion, number of bands
 NCT02645656

Curcumin
Recruiting
University of Arizona, USA
Rheumatoid arthritis
AE, pharmacokinetics, ESR, CRP
 NCT02543931

Source: https://www.clinicaltrials.gov/. A search performed using the keyword “curcumin” revealed 129 studies. Only active studies (48) were included in the table. Clinical trials that were complete (58), were withdrawn (8), were terminated (3), or have unknown status (12) were excluded.

CA: Canada; CCC: Comprehensive Cancer Center; CHU: Clermont-Ferrand University Hospital; HCL: Hospices Civiles de Lyon; NCI: National Cancer Institute; NNFTI: National Nutrition and Food Technology Institute; OSU: Ohio State University; SBUMS: Shahid Beheshti University of Medical Sciences; SHSC: Sunnybrook Health Sciences Centre; SVSIDS: Sri Venkata Sai Institute of Dental Sciences; TUMS: Tehran University of Medical Sciences; UCLA: University of California, Los Angeles; UK: United Kingdom; UNC: University of North Carolina; UPEI: University of Prince Edward Island; UPR: University of Puerto Rico; UT: University of Texas; USA: United States of America.5-ASA: 5-Aminosalicylic Acid; 5-FU: 5-Fluorouracil; AAA: Abdominal Aortic Aneurysm; AD: Alzheimer’s disease; ADPKD: Autosomal Dominant Polycystic Kidney Disease; AE: adverse events; ALT: Alanine Aminotransferase; AST: Aspartate Aminotransferase; CDRS-R: Children’s Depression Rating Scale-Revise; CIN: Cervical Intraepithelial Neoplasia; CK: Creatine Kinase; CKD: Chronic Kidney Disease; CLL: Chronic Lymphocytic Leukemia; CRP: C-Reactive Protein; DMII: Diabetes Mellitus Type 2; EGFR: epidermal growth factor receptor; eGFR: Estimated Glomerular Filtration Rate; ESR: Erythrocyte Sedimentation Rate; FAP: Familial Adenomatous Polyposis; FMD-BA: Brachial Artery Flow-Mediated Dilation; FOLFOX: Folinic Acid, 5-Fluorouracil, Oxaliplatin; GGT: Gamma-Glutamyl Transferase; GIM: Gastric Intestinal Metaplasia; GIQLI: Gastrointestinal Quality of Life Index; HA: headache; IHC: Immunohistochemistry; IL: Interleukin; MAG: Multifocal Atrophic Gastritis; MCCB: MATRICS Consensus Cognitive Battery; MCI: Mild Cognitive Impairment; NCI-WG: National Cancer Institute-Working Group; NAFLD: Nonalcoholic Fatty Liver Disease; NF-κB: nuclear factor kappa-light-chain-enhancer of activated B cells; NO: Nitric Oxide; NSCLC: Nonsmall Cell Lung Cancer; PANSS: Positive and Negative Syndrome Scale; PFS: Progression Free Survival; PSA: prostate-specific antigen; PUCAI: Pediatric Ulcerative Colitis Activity Index; QOL: quality of life; RT: Radiotherapy; SLL: Small Lymphocytic Lymphoma; TKI: Tyrosine Kinase Inhibitor; VA: Veterans Affairs.

6. Conclusion

The use of curcumin for the treatment of CNS tumors needs to be investigated. Preclinical data support its use in vitro and in vivo. In addition, there have been several limited studies demonstrating the safety of administration of oral curcumin in humans. Initial efficacy studies might focus on patients that have progressed on the current standard of care. As discussed previously, curcumin may also enhance the cytotoxic capabilities of other chemotherapeutics. Data also exists to suggest that curcumin might affect tumoral stem cell-like populations [16, 46, 97]. These stem cell-like features are found in nestin and CD133 positive cells are associated with higher grade and poor prognosis [46, 98, 99]. Adding curcumin to other chemotherapeutic regimens may aid in slowing or halting growth of these progenitor cells and thus their tumors. Since the administration of curcumin appears relatively safe, it could be added to current standard of care regimens in early or advanced disease. The greatest barrier to the use of curcumin as a therapeutic is its poor distribution to affected tissues. The use of delivery vehicles or curcumin derivatives may increase the efficacy of curcumin further by improving distribution, slowing degradation, and improving target specific affinity. Since individuals afflicted with brain tumors have such poor prognoses, there is a dire need to identify new therapeutic agents. As in the case with GBM, it is unfortunate that large clinical trials have been undertaken without identifying improvements to the standard of care that was formulated over 10 years ago [100–104]. Clinical trials should be undertaken to corroborate the benefits of curcumin seen in preclinical studies and improve the prognoses of individuals with brain tumors.

Competing Interests

The authors declare that there are no competing interests regarding the publication of this paper.

References

Q. T. Ostrom, H. Gittleman, P. Liao et al., “CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007–2011,” Neuro-Oncology, vol. 16, supplement 4, pp. iv1–iv63, 2014.

S.-P. Weathers and M. R. Gilbert, “Advances in treating glioblastoma,” F1000Prime Reports, vol. 6, article 46, 2014.

R. Stupp, M. E. Hegi, W. P. Mason et al., “Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial,” The Lancet Oncology, vol. 10, no. 5, pp. 459–466, 2009.

R. Stupp, W. P. Mason, M. J. Van Den Bent et al., “Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma,” The New England Journal of Medicine, vol. 352, no. 10, pp. 987–996, 2005.

D. R. Johnson, H. E. Leeper, and J. H. Uhm, “Glioblastoma survival in the United States improved after food and drug administration approval of bevacizumab: a population-based analysis,” Cancer, vol. 119, no. 19, pp. 3489–3495, 2013.

R. Stupp, S. Taillibert, A. A. Kanner et al., “Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma: a randomized clinical trial,” The Journal of the American Medical Association, vol. 314, no. 23, pp. 2535–2543, 2015.

B. B. Aggarwal, Y.-J. Surh, and S. Shishodia, The Molecular Targets and Therapeutic Uses of Curcumin in Health and Disease, Springer, 2007.

H. P. T. Ammon and M. A. Wahl, “Pharmacology of Curcuma longa,” Planta Medica, vol. 57, no. 1, pp. 1–7, 1991.

W.-H. Lee, C.-Y. Loo, M. Bebawy, F. Luk, R. S. Mason, and R. Rohanizadeh, “Curcumin and its derivatives: their application in neuropharmacology and neuroscience in the 21st century,” Current Neuropharmacology, vol. 11, no. 4, pp. 338–378, 2013.

A. Goel, A. B. Kunnumakkara, and B. B. Aggarwal, “Curcumin as ‘Curecumin’: from kitchen to clinic,” Biochemical Pharmacology, vol. 75, no. 4, pp. 787–809, 2008.

C. Schaaf, B. Shan, M. Buchfelder et al., “Curcumin acts as anti-tumorigenic and hormone-suppressive agent in murine and human pituitary tumour cells in vitro and in vivo,” Endocrine-Related Cancer, vol. 16, no. 4, pp. 1339–1350, 2009.

M. Miller, S. Chen, J. Woodliff, and S. Kansra, “Curcumin (diferuloylmethane) inhibits cell proliferation, induces apoptosis, and decreases hormone levels and secretion in pituitary tumor cells,” Endocrinology, vol. 149, no. 8, pp. 4158–4167, 2008.

B. H. Choi, C. G. Kim, Y.-S. Bae, Y. Lim, Y. H. Lee, and S. Y. Shin, “p21Waf1/Cip1 expression by curcumin in U-87MG human glioma cells: role of early growth response-1 expression,” Cancer Research, vol. 68, no. 5, pp. 1369–1377, 2008.

M. L. Y. Bangaru, S. Chen, J. Woodliff, and S. Kansra, “Curcumin (diferuloylmethane) induces apoptosis and blocks migration of human medulloblastoma cells,” Anticancer Research, vol. 30, no. 2, pp. 499–504, 2010.

A. Zanotto-Filho, E. Braganhol, K. Klafke et al., “Autophagy inhibition improves the efficacy of curcumin/temozolomide combination therapy in glioblastomas,” Cancer Letters, vol. 358, no. 2, pp. 220–231, 2015.

W. Zhuang, L. Long, B. Zheng et al., “Curcumin promotes differentiation of glioma-initiating cells by inducing autophagy,” Cancer Science, vol. 103, no. 4, pp. 684–690, 2012.

H. Aoki, Y. Takada, S. Kondo, R. Sawaya, B. B. Aggarwal, and Y. Kondo, “Evidence that curcumin suppresses the growth of malignant gliomas in vitro and in vivo through induction of autophagy: role of Akt and extracellular signal-regulated kinase signaling pathways,” Molecular Pharmacology, vol. 72, no. 1, pp. 29–39, 2007.

P. Langone, P. R. Debata, J. D. R. Inigo et al., “Coupling to a glioblastoma-directed antibody potentiates antitumor activity of curcumin,” International Journal of Cancer, vol. 135, no. 3, pp. 710–719, 2014.

S. Purkayastha, A. Berliner, S. S. Fernando et al., “Curcumin blocks brain tumor formation,” Brain Research, vol. 1266, pp. 130–138, 2009.

J. L. Arbiser, N. Klauber, R. Rohan et al., “Curcumin is an in vivo inhibitor of angiogenesis,” Molecular Medicine, vol. 4, no. 6, pp. 376–383, 1998.

S. Bisht, G. Feldmann, S. Soni et al., “Polymeric nanoparticle-encapsulated curcumin (‘nanocurcumin’): a novel strategy for human cancer therapy,” Journal of Nanobiotechnology, vol. 5, article 3, 18 pages, 2007.

M.-S. Woo, S.-H. Jung, S.-Y. Kim et al., “Curcumin suppresses phorbol ester-induced matrix metalloproteinase-9 expression by inhibiting the PKC to MAPK signaling pathways in human astroglioma cells,” Biochemical and Biophysical Research Communications, vol. 335, no. 4, pp. 1017–1025, 2005.

S.-Y. Kim, S.-H. Jung, and H.-S. Kim, “Curcumin is a potent broad spectrum inhibitor of matrix metalloproteinase gene expression in human astroglioma cells,” Biochemical and Biophysical Research Communications, vol. 337, no. 2, pp. 510–516, 2005.

S. S. Bhandarkar and J. L. Arbiser, “Curcumin as an inhibitor of angiogenesis,” in The Molecular Targets and Therapeutic Uses of Curcumin in Health and Disease, pp. 185–195, Springer, 2007.

D. Thaloor, A. K. Singh, G. S. Sidhu, P. V. Prasad, H. K. Kleinman, and R. K. Maheshwari, “Inhibition of angiogenic differentiation of human umbilical vein endothelial cells by curcumin,” Cell Growth and Differentiation, vol. 9, no. 4, pp. 305–312, 1998.

B. E. Bachmeier, A. G. Nerlich, C. M. Iancu et al., “The chemopreventive polyphenol curcumin prevents hematogenous breast cancer metastases in immunodeficient mice,” Cellular Physiology and Biochemistry, vol. 19, no. 1–4, pp. 137–152, 2007.

J. Ravindran, S. Prasad, and B. B. Aggarwal, “Curcumin and cancer cells: how many ways can curry kill tumor cells selectively?” The AAPS Journal, vol. 11, no. 3, pp. 495–510, 2009.

G. Sa and T. Das, “Anti cancer effects of curcumin: cycle of life and death,” Cell Division, vol. 3, no. 1, article 14, 2008.

N. Hasima and B. B. Aggarwal, “Cancer-linked targets modulated by curcumin,” International Journal of Biochemistry and Molecular Biology, vol. 3, no. 4, pp. 328–351, 2012.

P. Anand, C. Sundaram, S. Jhurani, A. B. Kunnumakkara, and B. B. Aggarwal, “Curcumin and cancer: an ‘old-age’ disease with an ‘age-old’ solution,” Cancer Letters, vol. 267, no. 1, pp. 133–164, 2008.

H. Hatcher, R. Planalp, J. Cho, F. M. Torti, and S. V. Torti, “Curcumin: from ancient medicine to current clinical trials,” Cellular and Molecular Life Sciences, vol. 65, no. 11, pp. 1631–1652, 2008.

P. Rathore, P. Dohare, S. Varma et al., “Curcuma oil: reduces early accumulation of oxidative product and is anti-apoptogenic in transient focal ischemia in rat brain,” Neurochemical Research, vol. 33, no. 9, pp. 1672–1682, 2008.

J.-X. Wu, L.-Y. Zhang, Y.-L. Chen, S.-S. Yu, Y. Zhao, and J. Zhao, “Curcumin pretreatment and post-treatment both improve the antioxidative ability of neurons with oxygen-glucose deprivation,” Neural Regeneration Research, vol. 10, no. 3, pp. 481–489, 2015.

T. Santel, G. Pflug, N. Y. A. Hemdan et al., “Curcumin inhibits glyoxalase 1—a possible link to its anti-inflammatory and anti-tumor activity,” PLoS ONE, vol. 3, no. 10, Article ID e3508, 2008.

B. Wu, H. Yao, S. Wang, and R. Xu, “DAPK1 modulates a curcumin-induced G2/M arrest and apoptosis by regulating STAT3, NF-κB, and caspase-3 activation,” Biochemical and Biophysical Research Communications, vol. 434, no. 1, pp. 75–80, 2013.

E. Liu, J. Wu, W. Cao et al., “Curcumin induces G2/M cell cycle arrest in a p53-dependent manner and upregulates ING4 expression in human glioma,” Journal of Neuro-Oncology, vol. 85, no. 3, pp. 263–270, 2007.

I. Garkavtsev, S. V. Kozin, O. Chernova et al., “The candidate tumour suppressor protein ING4 regulates brain tumour growth and angiogenesis,” Nature, vol. 428, no. 6980, pp. 328–332, 2004.

Y. Qian, J. Ma, X. Guo et al., “Curcumin enhances the radiosensitivity of U87 cells by inducing DUSP-2 up-regulation,” Cellular Physiology and Biochemistry, vol. 35, no. 4, pp. 1381–1393, 2015.

B. Pauwels, A. Wouters, M. Peeters, J. B. Vermorken, and F. Lardon, “Role of cell cycle perturbations in the combination therapy of chemotherapeutic agents and radiation,” Future Oncology, vol. 6, no. 9, pp. 1485–1496, 2010.

N. Aravindan, R. Madhusoodhanan, S. Ahmad, D. Johnson, and T. S. Herman, “Curcumin inhibits NFκB mediated radioprotection and modulate apoptosis related genes in human neuroblastoma cells,” Cancer Biology and Therapy, vol. 7, no. 4, pp. 569–576, 2008.

A. K. Khaw, M. P. Hande, G. Kalthur, and M. P. Hande, “Curcumin inhibits telomerase and induces telomere shortening and apoptosis in brain tumour cells,” Journal of Cellular Biochemistry, vol. 114, no. 6, pp. 1257–1270, 2013.

T.-Y. Huang, T.-H. Tsai, C.-W. Hsu, and Y.-C. Hsu, “Curcuminoids suppress the growth and induce apoptosis through caspase-3-dependent pathways in glioblastoma multiforme (GBM) 8401 cells,” Journal of Agricultural and Food Chemistry, vol. 58, no. 19, pp. 10639–10645, 2010.

S. Karmakar, N. L. Banik, and S. K. Ray, “Curcumin suppressed anti-apoptotic signals and activated cysteine proteases for apoptosis in human malignant glioblastoma U87MG cells,” Neurochemical Research, vol. 32, no. 12, pp. 2103–2113, 2007.

D. W. Davis, D. J. McConkey, J. L. Abbruzzese, and R. S. Herbst, “Surrogate markers in antiangiogenesis clinical trials,” British Journal of Cancer, vol. 89, no. 1, pp. 8–14, 2003.

A. Zanotto-Filho, E. Braganhol, R. Schröder et al., “NFκB inhibitors induce cell death in glioblastomas,” Biochemical Pharmacology, vol. 81, no. 3, pp. 412–424, 2011.

I. Bandey, S.-H. Chiou, A.-P. Huang, J.-C. Tsai, and P.-H. Tu, “Progranulin promotes Temozolomide resistance of glioblastoma by orchestrating DNA repair and tumor stemness,” Oncogene, vol. 34, no. 14, pp. 1853–1864, 2015.

K. M. Dhandapani, V. B. Mahesh, and D. W. Brann, “Curcumin suppresses growth and chemoresistance of human glioblastoma cells via AP-1 and NFκB transcription factors,” Journal of Neurochemistry, vol. 102, no. 2, pp. 522–538, 2007.

A. Belkaid, I. B. Copland, D. Massillon, and B. Annabi, “Silencing of the human microsomal glucose-6-phosphate translocase induces glioma cell death: potential new anticancer target for curcumin,” FEBS Letters, vol. 580, no. 15, pp. 3746–3752, 2006.

J. Weissenberger, M. Priester, C. Bernreuther et al., “Dietary curcumin attenuates glioma growth in a syngeneic mouse model by inhibition of the JAK1, 2/STAT3 signaling pathway,” Clinical Cancer Research, vol. 16, no. 23, pp. 5781–5795, 2010.

M. H. Elamin, Z. Shinwari, S.-F. Hendrayani et al., “Curcumin inhibits the sonic hedgehog signaling pathway and triggers apoptosis in medulloblastoma cells,” Molecular Carcinogenesis, vol. 49, no. 3, pp. 302–314, 2010.

W.-Z. Du, Y. Feng, X.-F. Wang et al., “Curcumin suppresses malignant glioma cells growth and induces apoptosis by inhibition of SHH/GLI1 signaling pathway in vitro and vivo,” CNS Neuroscience & Therapeutics, vol. 19, no. 12, pp. 926–936, 2013.

M. He, Y. Li, L. Zhang et al., “Curcumin suppresses cell proliferation through inhibition of the Wnt/β-catenin signaling pathway in medulloblastoma,” Oncology Reports, vol. 32, no. 1, pp. 173–180, 2014.

S. J. Lee, C. Krauthauser, V. Maduskuie, P. T. Fawcett, J. M. Olson, and S. A. Rajasekaran, “Curcumin-induced HDAC inhibition and attenuation of medulloblastoma growth in vitro and in vivo,” BMC Cancer, vol. 11, article 114, 2011.

N. A. A. Thani, B. Sallis, R. Nuttall et al., “Induction of apoptosis and reduction of MMP gene expression in the U373 cell line by polyphenolics in Aronia melanocarpa and by curcumin,” Oncology Reports, vol. 28, no. 4, pp. 1435–1442, 2012.

K. Tsunoda, G. Kitange, T. Anda et al., “Expression of the constitutively activated RelA/NF-κB in human astrocytic tumors and the in vitro implication in the regulation of urokinase-type plasminogen activator, migration, and invasion,” Brain Tumor Pathology, vol. 22, no. 2, pp. 79–87, 2005.

B. Shan, C. Schaaf, A. Schmidt et al., “Curcumin suppresses HIF1A synthesis and VEGFA release in pituitary adenomas,” Journal of Endocrinology, vol. 214, no. 3, pp. 389–398, 2012.

A. Zanotto-Filho, E. Braganhol, M. I. Edelweiss et al., “The curry spice curcumin selectively inhibits cancer cells growth in vitro and in preclinical model of glioblastoma,” The Journal of Nutritional Biochemistry, vol. 23, no. 6, pp. 591–601, 2012.

C. Ramachandran, S. M. Nair, E. Escalon, and S. J. Melnick, “Potentiation of etoposide and temozolomide cytotoxicity by curcumin and turmeric force™ in brain tumor cell lines,” Journal of Complementary and Integrative Medicine, vol. 9, no. 1, article 20, 2012.

M. M. Hossain, N. L. Banik, and S. K. Ray, “Synergistic anti-cancer mechanisms of curcumin and paclitaxel for growth inhibition of human brain tumor stem cells and LN18 and U138MG cells,” Neurochemistry International, vol. 61, no. 7, pp. 1102–1113, 2012.

S. Shukla, H. Zaher, A. Hartz, B. Bauer, J. A. Ware, and S. V. Ambudkar, “Curcumin inhibits the activity of ABCG2/BCRP1, a multidrug resistance-linked ABC drug transporter in mice,” Pharmaceutical Research, vol. 26, no. 2, pp. 480–487, 2009.

I. Zhang, Y. Cui, A. Amiri, Y. Ding, R. E. Campbell, and D. Maysinger, “Pharmacological inhibition of lipid droplet formation enhances the effectiveness of curcumin in glioblastoma,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 100, pp. 66–76, 2016.

P. M. Luthra, R. Kumar, and A. Prakash, “Demethoxycurcumin induces Bcl-2 mediated G2/M arrest and apoptosis in human glioma U87 cells,” Biochemical and Biophysical Research Communications, vol. 384, no. 4, pp. 420–425, 2009.

T.-Y. Huang, C.-W. Hsu, W.-C. Chang, M.-Y. Wang, J.-F. Wu, and Y.-C. Hsu, “Demethoxycurcumin retards cell growth and induces apoptosis in human brain malignant glioma GBM 8401 cells,” Evidence-Based Complementary and Alternative Medicine, vol. 2012, Article ID 396573, 11 pages, 2012.

C. A. Campos, J. B. Gianino, B. J. Bailey et al., “Design, synthesis, and evaluation of curcumin-derived arylheptanoids for glioblastoma and neuroblastoma cytotoxicity,” Bioorganic and Medicinal Chemistry Letters, vol. 23, no. 24, pp. 6874–6878, 2013.

Y.-M. Tsai, C.-F. Chien, L.-C. Lin, and T.-H. Tsai, “Curcumin and its nano-formulation: the kinetics of tissue distribution and blood-brain barrier penetration,” International Journal of Pharmaceutics, vol. 416, no. 1, pp. 331–338, 2011.

B. S. Patil, G. K. Jayaprakasha, K. N. Chidambara Murthy, and A. Vikram, “Bioactive compounds: historical perspectives, opportunities, and challenges,” Journal of Agricultural and Food Chemistry, vol. 57, no. 18, pp. 8142–8160, 2009.

C. D. Lao, M. T. Ruffin, D. Normolle et al., “Dose escalation of a curcuminoid formulation,” BMC Complementary and Alternative Medicine, vol. 6, no. 1, article 10, 2006.

A.-L. Chen, C.-H. Hsu, J.-K. Lin et al., “Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions,” Anticancer Research, vol. 21, no. 4, pp. 2895–2900, 2001.

G. Shoba, D. Joy, T. Joseph, M. Majeed, R. Rajendran, and P. S. S. R. Srinivas, “Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers,” Planta Medica, vol. 64, no. 4, pp. 353–356, 1998.

C. K. Atal, R. K. Dubey, and J. Singh, “Biochemical basis of enhanced drug bioavailability by piperine: evidence that piperine is a potent inhibitor of drug metabolism,” Journal of Pharmacology and Experimental Therapeutics, vol. 232, no. 1, pp. 258–262, 1985.

C. K. Atal, U. Zutshi, and P. G. Rao, “Scientific evidence on the role of Ayurvedic herbals on bioavailability of drugs,” Journal of Ethnopharmacology, vol. 4, no. 2, pp. 229–232, 1981.

P. Anand, A. B. Kunnumakkara, R. A. Newman, and B. B. Aggarwal, “Bioavailability of curcumin: problems and promises,” Molecular Pharmaceutics, vol. 4, no. 6, pp. 807–818, 2007.

R. S. Mulik, J. Mönkkönen, R. O. Juvonen, K. R. Mahadik, and A. R. Paradkar, “ApoE3 mediated polymeric nanoparticles containing curcumin: apoptosis induced in vitro anticancer activity against neuroblastoma cells,” International Journal of Pharmaceutics, vol. 437, no. 1-2, pp. 29–41, 2012.

Y. Chen, L. Pan, M. Jiang, D. Li, and L. Jin, “Nanostructured lipid carriers enhance the bioavailability and brain cancer inhibitory efficacy of curcumin both in vitro and in vivo,” Drug Delivery, vol. 23, no. 4, pp. 1383–1392, 2016.

M. T. Mirgani, B. Isacchi, M. Sadeghizadeh et al., “Dendrosomal curcumin nanoformulation downregulates pluripotency genes via miR-145 activation in U87MG glioblastoma cells,” International Journal of Nanomedicine, vol. 9, no. 1, pp. 403–417, 2014.

E. Babaei, M. Sadeghizadeh, Z. M. Hassan, M. A. H. Feizi, F. Najafi, and S. M. Hashemi, “Dendrosomal curcumin significantly suppresses cancer cell proliferation in vitro and in vivo,” International Immunopharmacology, vol. 12, no. 1, pp. 226–234, 2012.

V. Erfani-Moghadam, A. Nomani, M. Zamani, Y. Yazdani, F. Najafi, and M. Sadeghizadeh, “A novel diblock copolymer of (monomethoxy poly [ethylene glycol]-oleate) with a small hydrophobic fraction to make stable micelles/polymersomes for curcumin delivery to cancer cells,” International Journal of Nanomedicine, vol. 9, no. 1, pp. 5541–5554, 2014.

X. Zhuang, X. Xiang, W. Grizzle et al., “Treatment of brain inflammatory diseases by delivering exosome encapsulated anti-inflammatory drugs from the nasal region to the brain,” Molecular Therapy, vol. 19, no. 10, pp. 1769–1779, 2011.

R. G. Madane and H. S. Mahajan, “Curcumin-loaded nanostructured lipid carriers (NLCs) for nasal administration: design, characterization, and in vivo study,” Drug Delivery, vol. 23, no. 4, pp. 1326–1334, 2016.

B. Farhangi, A. M. Alizadeh, H. Khodayari et al., “Protective effects of dendrosomal curcumin on an animal metastatic breast tumor,” European Journal of Pharmacology, vol. 758, pp. 188–196, 2015.

Z.-J. Sun, B. Sun, R.-B. Tao, X. Xie, X.-L. Lu, and D.-L. Dong, “A poly(glycerol-sebacate-curcumin) polymer with potential use for brain gliomas,” Journal of Biomedical Materials Research Part A, vol. 101, no. 1, pp. 253–260, 2013.

G. Guo, S. Fu, L. Zhou et al., “Preparation of curcumin loaded poly(-caprolactone)-poly(ethylene glycol)-poly(-caprolactone) nanofibers and their in vitro antitumor activity against Glioma 9L cells,” Nanoscale, vol. 3, no. 9, pp. 3825–3832, 2011.

R. C. Gupta, S. S. Bansal, F. Aqil et al., “Controlled-release systemic delivery—a new concept in cancer chemoprevention,” Carcinogenesis, vol. 33, no. 8, pp. 1608–1615, 2012.

K. Shahani, S. K. Swaminathan, D. Freeman, A. Blum, L. Ma, and J. Panyam, “Injectable sustained release microparticles of curcumin: a new concept for cancer chemoprevention,” Cancer Research, vol. 70, no. 11, pp. 4443–4452, 2010.

S. Bisht, M. Mizuma, G. Feldmann et al., “Systemic administration of polymeric nanoparticle-encapsulated curcumin (NanoCurc) blocks tumor growth and metastases in preclinical models of pancreatic cancer,” Molecular Cancer Therapeutics, vol. 9, no. 8, pp. 2255–2264, 2010.

K. J. Lim, S. Bisht, E. E. Bar, A. Maitra, and C. G. Eberhart, “A polymeric nanoparticle formulation of curcumin inhibits growth, clonogenicity and stem-like fraction in malignant brain tumors,” Cancer Biology & Therapy, vol. 11, no. 5, pp. 464–473, 2011.

F. Dilnawaz and S. K. Sahoo, “Enhanced accumulation of curcumin and temozolomide loaded magnetic nanoparticles executes profound cytotoxic effect in glioblastoma spheroid model,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 85, no. 3, pp. 452–462, 2013.

J.-H. Fang, Y.-H. Lai, T.-L. Chiu, Y.-Y. Chen, S.-H. Hu, and S.-Y. Chen, “Magnetic core–shell nanocapsules with dual-targeting capabilities and co-delivery of multiple drugs to treat brain gliomas,” Advanced Healthcare Materials, vol. 3, no. 8, pp. 1250–1260, 2014.

P. Langone, P. R. Debata, S. Dolai et al., “Coupling to a cancer cell-specific antibody potentiates tumoricidal properties of curcumin,” International Journal of Cancer, vol. 131, no. 4, pp. E569–E578, 2012.

E.-M. Strasser, B. Wessner, N. Manhart, and E. Roth, “The relationship between the anti-inflammatory effects of curcumin and cellular glutathione content in myelomonocytic cells,” Biochemical Pharmacology, vol. 70, no. 4, pp. 552–559, 2005.

M. Yoshino, M. Haneda, M. Naruse et al., “Prooxidant activity of curcumin: copper-dependent formation of 8-hydroxy-2′-deoxyguanosine in DNA and induction of apoptotic cell death,” Toxicology in Vitro, vol. 18, no. 6, pp. 783–789, 2004.

K. Sakano and S. Kawanishi, “Metal-mediated DNA damage induced by curcumin in the presence of human cytochrome P450 isozymes,” Archives of Biochemistry and Biophysics, vol. 405, no. 2, pp. 223–230, 2002.

J. Nair, S. Strand, N. Frank et al., “Apoptosis and age-dependant induction of nuclear and mitochondrial etheno-DNA adducts in Long-Evans Cinnamon (LEC) rats: enhanced DNA damage by dietary curcumin upon copper accumulation,” Carcinogenesis, vol. 26, no. 7, pp. 1307–1315, 2005.

N. Frank, J. Knauft, F. Amelung, J. Nair, H. Wesch, and H. Bartsch, “No prevention of liver and kidney tumors in Long-Evans Cinnamon rats by dietary curcumin, but inhibition at other sites and of metastases,” Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, vol. 523-524, pp. 127–135, 2003.

P. J. Moos, K. Edes, J. E. Mullally, and F. A. Fitzpatrick, “Curcumin impairs tumor suppressor p53 function in colon cancer cells,” Carcinogenesis, vol. 25, no. 9, pp. 1611–1617, 2004.

S. Somasundaram, N. A. Edmund, D. T. Moore, G. W. Small, Y. Y. Shi, and R. Z. Orlowski, “Dietary curcumin inhibits chemotherapy-induced apoptosis in models of human breast cancer,” Cancer Research, vol. 62, no. 13, pp. 3868–3875, 2002.

D. Fong, A. Yeh, R. Naftalovich, T. H. Choi, and M. M. Chan, “Curcumin inhibits the side population (SP) phenotype of the rat C6 glioma cell line: towards targeting of cancer stem cells with phytochemicals,” Cancer Letters, vol. 293, no. 1, pp. 65–72, 2010.

R. Galli, E. Binda, U. Orfanelli et al., “Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma,” Cancer Research, vol. 64, no. 19, pp. 7011–7021, 2004.

M. Zhang, T. Song, L. Yang et al., “Nestin and CD133: valuable stem cell-specific markers for determining clinical outcome of glioma patients,” Journal of Experimental & Clinical Cancer Research, vol. 27, no. 1, article 85, 1 pages, 2008.

M. R. Gilbert, J. J. Dignam, T. S. Armstrong et al., “A randomized trial of bevacizumab for newly diagnosed glioblastoma,” The New England Journal of Medicine, vol. 370, no. 8, pp. 699–708, 2014.

M. R. Gilbert, M. Wang, K. D. Aldape et al., “Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial,” Journal of Clinical Oncology, vol. 31, no. 32, pp. 4085–4091, 2013.

O. L. Chinot, W. Wick, W. Mason et al., “Bevacizumab plus radiotherapy–temozolomide for newly diagnosed glioblastoma,” The New England Journal of Medicine, vol. 370, no. 8, pp. 709–722, 2014.

M. Westphal, O. Heese, J. P. Steinbach et al., “A randomised, open label phase III trial with nimotuzumab, an anti-epidermal growth factor receptor monoclonal antibody in the treatment of newly diagnosed adult glioblastoma,” European Journal of Cancer, vol. 51, no. 4, pp. 522–532, 2015.

R. Stupp, M. E. Hegi, T. Gorlia et al., “Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial,” The Lancet Oncology, vol. 15, no. 10, pp. 1100–1108, 2014.